Skip to main content
Clinical Trials/CTRI/2023/10/058731
CTRI/2023/10/058731
Completed
未知

Skin irritation and skin sensitization potential (Allergenicity) of 4 test products using HumanRepeat Insult Patch Test (HRIPT) IS 4011:2018 Guidelines. - NI

Dabur Research and Development Centre0 sites209 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Dabur Research and Development Centre
Enrollment
209
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 20, 2024
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dabur Research and Development Centre

Eligibility Criteria

Inclusion Criteria

  • 1\. Voluntary men and women between 18 and 65 years, with 50 participants having sensitive
  • skin as determined by lactic acid sting test.
  • 2\. Fitzpatrick skin type III to V.
  • 3\. Having apparently healthy skin on test area.
  • 4\. Willingness to discontinue the use of cleansing and/or cosmetic products in the application
  • areas during the course of the trial.
  • 5\. Cooperating, informed of the need and duration of the examinations, and ready to comply
  • with protocol procedures.
  • 6\. Willing to give written informed consent to participate in the trial after informing all
  • information concerning the trial procedures and trial objectives.

Exclusion Criteria

  • 1\. Pregnancy (by UPT) and lactating women.
  • 2\. Scars, excessive terminal hair, or tattoo on the studied area.
  • 3\. A participant who the Investigator feels will not be compliant with trial requirements.
  • 4\. Dermatological infection/pathology on the level of studied area.
  • 5\. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
  • 6\. Any clinically significant systemic or cutaneous disease, which may interfere with trial
  • procedures.
  • 7\. Chronic illness which may influence the outcome of the trial.
  • 8\. Participants on any medical treatment either systemic or topical which may interfere with
  • the performance of the trial (presently or in the past 1 month).

Outcomes

Primary Outcomes

Not specified

Similar Trials